The biogenesis of silver nanoparticles by fungi is an ecologically clean and nontoxic method compared to other physical and chemical methods. Thus, we aimed to discuss the mycosynthesis of extracellular size-controlled AgNPs. After comprehensive screening, Aspergillus fumigatus BTCB10 (KY486782) was selected for the synthesis of AgNPs of controlled size. Characterization was performed by UV-Vis spectrophotometer, Zetasizer, X-Ray Diffraction (XRD), FTIR (Fourier-transform infrared), Atomic Force Microscopy (AFM), and Scanning Electron Microscopy (SEM) along with functional assays—antibacterial and MTT assays. Data suggested that under optimized conditions, i.e., temperature 25°C, AgNO3 concentration 1 mM, biomass 7 g, fungal culture age 7 days, pH 6, ratio of cell-free filtrate (CFF)/silver nitrate (3 : 2), NaCl 20%, and under dark light, the smallest size AgNPs of 0.681 nm with 100% monodispersity was obtained as evident by a zeta potential of -23.4 mV, UV-Vis band at 400 nm, and the presence of O-H and C=O groups confirmed by ATR-FTIR; XRD revealed the crystalline nature of AgNPs; additionally, cube-shaped AgNPs were revealed by Scanning Electron Microscopy (SEM). Moreover, synthesized AgNPs exhibited antibacterial activity against multidrug-resistant bacterial strains, notably, Klebsiella pneumoniae BTCB04, Acinetobacter BTCB05, Pseudomonas aeruginosa BTCB01, and Escherichia coli BTCB03, while maximum 7-fold was observed with Acinetobacter BTCB05. AgNPs demonstrated no cytotoxic activity against HepG2 cells; however, in combination with cisplatin, antiproliferative and cytotoxic effects became more evident and significant in comparison to control and as single agent. Taken together, the data suggested that economical and smallest size AgNPs can be biosynthesized from Aspergillus fumigatus BTCB10 and be used as antibacterial and antiproliferative agents in combination with current drugs against clinically relevant multiple drug-resistant bacterial and tumoral cells. Further studies are required to confirm their effects employing in vivo disease models.

Background: Plants are the natural source of antioxidants as well as antimicrobial compounds that has great potentials in pharmaceutical industry. In the present study, two medicinal plants Atropa belladonna and Matricaria chamomilla were collected from Northern areas of Pakistan. Materials and Methods:The extracts of the collected plants were obtained by microwave assisted extraction (MAE) with changing parameters, power level and time; methanol and ethanol were solvents used during extraction. The extracts of plants were tested against different bacterial strains. Results: It was observed that ethanolic extracts of Atropa belladonna has more significant antimicrobial activity against S.aureus than E.coli. In parallel, methanolic extract of Matricaria chamomilla showed greater significant antibacterial activity against S.aureus when compared with E.coli. In comparison, ethanolic extracts of Matricaria chamomilla has shown more significant results against S. aureus than E.coli (p≤0.05). Both plants had no antibacterial activity against S.typhi. The free radical scavenging activity observed by DPPH assay, indicate that both plants have antioxidant activity at all levels of concentrations in solvent tested during the present work. However, methanolic extracts had greater antioxidant activity when compared with ethanolic extracts. Conclusion: Present study is thus helpful in highlighting present potentials for antioxidant and antimicrobial properties in the selected plants.

Bacillus thuringiensis (Bt) is the most successful, environmentally-friendly, and intensively studied microbial insecticide. The major characteristic of Bt is the production of proteinaceous crystals containing toxins with specific activity against many pests including dipteran, lepidopteran, and coleopteran insects, as well as nematodes, protozoa, flukes, and mites. These crystals allow large quantities of the protein toxins to remain stable in the environment until ingested by a susceptible host. It has been previously established that 135 kDa Cry proteins have a crystallization domain at their C-terminal end. In the absence of this domain, Cry proteins often need helper proteins or other factors for crystallization. In this review, we classify the Cry proteins based on their requirements for crystallization.

No abstract